In recent years several radiotracers targeting the prostate-specific membrane antigen (PSMA) have been introduced. Few of those had a high clinical impact for the treatment of patients suffering from prostate cancer. However, the number of fluorine-18 labeled tracers addressing PSMA is still limited. Therefore, we aimed at the development of a radiofluorinated molecule with emphasis on resembling the structure of the therapeutic PSMA-617.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
The non-radioactive reference compound PSMA-1007 and the labeling precursor were built up by solid phase chemistry. The radioligand (18)F-PSMA-1007 was produced via a two-step procedure using the prosthetic group 6-(18)F-fluoronicotinic acid 2,3,5,6-tetrafluorophenyl ester (6-(18)F-F-Py-TFP). The binding affinity of the ligand towards PSMA and its internalization properties were evaluated in vitro using PSMA-positive LNCaP (Lymph Node Carcinoma of the Prostate) cells. Further, organ distribution studies were performed using LNCaP- and PC-3 (Prostate Cancer cell line; PSMA negative) tumor bearing mice. Finally, a microPET (small animal Positron Emission Tomography) imaging with an LNCaP tumor bearing mouse was carried out.
The identified ligand revealed a binding affinity of 6.7±1.7 nM towards PSMA and an exceptional high internalization ratio of 67±13 % in vitro. In organ distribution studies a high and specific tumor uptake of 8.0±2.4 %ID/g in LNCaP tumor bearing mice was observed. In further microPET experiments LNCaP tumors were clearly visualized.
The radiofluorinated PSMA-ligand showed promising characteristics in its preclinical evaluation and the feasibility of prostate cancer imaging was demonstrated by microPET studies. Thus, we recommend the ligand (18)F-PSMA-1007 for clinical transfer as diagnostic PET tracer for prestaging and monitoring of prostate cancer.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2016 Oct 27 [Epub ahead of print]
Jens Cardinale, Martin Schäfer, Martina Benešová, Ulrike Bauder-Wüst, Karin Leotta, Matthias Eder, Oliver C Neels, Uwe Haberkorn, Frederik L Giesel, Klaus Kopka
German Cancer Research Center, Germany., German Cancer Research Center (DKFZ)., University Hospital Heidelberg.